8月31日 - ** 康希诺生物6185.HK领跌香港上市的中国疫苗股，此前有消息称 BioNTech 22UAy.DE 因安全审查而暂停了 (link) mRNA 结直肠癌疫苗的临床试验
** 康希诺香港股价下跌8.6%至29.02港元，上海股价 688185.SS 下跌9.4%至75.08元
** BioNTech表示，在独立委员会认定该疗法不太可能帮助结直肠癌患者延长生存期后，公司将终止其实验性mRNA癌症疫苗的中期研究，受此影响，该公司周五在美国市场的股价下跌
** BioNTech的试验失败发生在默克公司 MRK.N 和莫德纳公司 MRNA.O 宣布其mRNA疫苗在试验中有助于预防黑色素瘤复发和扩散仅数日之后；该成功曾为同类mRNA疫苗带来了希望
** 赛诺生物 1177.HK、基因科技 1548.HK、信达生物 1801.HK、药明生物 2269.HK 以及艾克索 9926.HK 的股价均下跌3.3%至5.4%
** 中国中证疫苗与生物科技指数 .CSI931992 下跌3.1%，香港恒生生物科技指数 .HSBIO 下跌4.4%，恒生创新药指数 .HSIDI 下跌4.6%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.